Protein kinase C (PKC) modulating activity of 81 plant extracts of Finnish origin was investigated with an automated bioassay method combined to LC/MS. Twenty-one extracts from different parts of the plants inhibited PKC significantly. Fractionation of the active extract of Filipendula ulmaria showed that this method was able to identify a PKC inhibiting compound from the extract as quercetin. Our results indicate that this method is suitable for PKC screening of complex matrices and provides a quick and low volume, non-radioactive, alternative method for PKC experiments.
Protein kinase C (PKC) represents a family of closely related serine/threonine kinases involved in the transduction of signals for cell proliferation, differentiation and regulation of apoptosis [1, 2] . More than 12 isoforms with different tissue expressions, substrate specificity and subcellular localization have been described [3] . Protein kinase isoforms consist of a single polypeptide chain that contains an amino terminal regulatory domain and a carboxy terminal catalytic domain [4] . Different isoforms are divided into subclasses based on their diacylglycerol, phosphatidylserine, calcium and phorbol ester requirements for activation. Protein kinases have been implicated in having a role in various diseases including cancer, autoimmune disorders, diabetes, vascular diseases and degenerative brain diseases [3,5a-5c ]. Multiple functions of PKCs make them an interesting target for drug discovery. Targeted influence on PKC activity is though challenging due to opposite roles of different isoforms, broad and partly overlapping substrate specificity, and existence of multiple isoforms in a single cell type [6a,6b] .
Natural products have been shown to regulate PKC activity and, therefore, interest towards them as PKC modulators has increased [5a,7] . For example, the potent and specific PKC inhibitor staurosporin is an alkaloid from Streptomyces sp. [8] . Many PKC modulating compounds could also be gained from common food [5a,9] . Flavonoids are polyphenolic secondary metabolites that are universally represented throughout the plant kingdom. Plants containing flavonoids have been used for thousands of years in Eastern medicine. Green tea, berries, vegetables, dark chocolate, onions and red wine are very rich sources of flavonoids and possess health beneficial effects, including antioxidant, reduction in coronary heart disease, and cancer chemopreventive activity [7, 9] . Some flavonoids, including luteolin, quercetin and myricetin, have been shown to possess PKC modulating activity [10a-10c] and thus these compounds were used as model substances in our studies. Initial PKC activity reduced after treatment with these compounds in a dose dependent manner. luteolin, quercetin and myricetin are presented in Figure 1 .
Plants growing in the stress conditions set by the northern climate provide an interesting source for bioactivity studies. Thus, PKC modulating activity of 81 plant extracts from different parts of plants (stem, leaf, flower and root), from 23 species collected in Finland, were investigated. The plants were selected randomly from an existing natural product library (see Experimental).
Twenty-one extracts from 7 plants inhibited PKC activity significantly. Extracts of all studied parts of Epilobium parviflorum, Filipendula ulmaria, Lysimachia vulgaris, Hypericum maculatum and
Calluna vulgaris, as well as root extract of Myosotis scorpioides, and leaf and root extracts of Pteridium aquilinum inhibited PKC extensively. Other plant extracts showed less or no PKC activity at the studied concentration. The results are presented in Table 1 .
The active leaf extract of Filipendula ulmaria was studied further. As it is known that bioactive compounds can be in an inactive form such as sugar conjugates, the extract was hydrolyzed prior to LC fractionation and LC/MS analysis. The flavonoid compound quercetin could be identified as a component of the fraction (Figure 2 ). The identification of quercetin was based on the retention time, UV spectrum, MS studies and by comparison with the reference compound. Also, some other compounds from the extract seemed to inhibit PKC. In particular, a compound eluting at 29 min ( Figure 2 ) showed strong inhibition and the structure elucidation of this compound is ongoing. Fully activated (n=6) and non-activated PKC (n=6), measured together with sample extracts to assess the functionality of the assay, showed deviation of 5.4% and 4.8%, respectively. The result indicates the reproducibility of the enzymatic assay.
In previous studies, the whole herb of F. ulmaria from our collections has been shown to possess antibacterial activity and antioxidant potential [11a,11b] . In other studies, F. ulmaria has been shown to inhibit carcinogenesis, suppress cell growth [12a,12b] and promote healing of chronic ulcers [13] . The latter effects could be related to PKC inhibition activity. These studies have been made using either a flower decoction or an ethanol extract of F. ulmaria. Our studies showed that PKC inhibition can be induced with leaf, root, and stem extracts of the plant and the PKC activity was to some part due to the quercetin content of the extracts. Taken together, the results showed that our method is suitable for PKC screening purposes for complex plant based matrices and provides quick and low volume non-radioactive assay for PKC experiments.
Experimental
General: Methanol (MeOH) was purchased from J.T. Baker (Deventer, Holland) and dimethylsulfoxide (DMSO) and hydrochloric acid from Merck (Darmstadt, Germany). Formic acid and mineral oil were obtained from Fluka (Buchs, Switzerland) and 2-propanol from Riedel-de Haën (Seelze, Germany). Acroprep™ 384 filter plate 0.45 µm GHP was obtained from Pall (Michigan, USA) and milliQ water was prepared with a Millipore Milli-Q plus system (Molsheim, France).
Plant material and extraction:
The plants used were obtained from the herb collection of the Division of Pharmaceutical Biology, Faculty of Pharmacy, University of Helsinki. The plants were collected in summer 2000 from Helsinki and the North Carelia region and identified by Dr Pia Fyhrquist. Air-dried and powdered plant material (1 g) was extracted with 5 mL of methanol three times using 10 minutes sonication and 15 minutes centrifugation at 1500 g. Combined supernatants were first frozen and then lyophilized. Freeze dried samples were weighed and dissolved in DMSO yielding a concentration of 40 mg/mL.
PKC-assay:
A high throughput method for natural products PKC-activity screening was set up on a Beckman Coulter Biomek FX robotic workstation. The assay included dilution of the lyophilized extracts with 3 µL of DMSO (if needed), addition of 96 µL of reaction mixture, initiation of the enzymatic reaction with 26 µL of 11 µg/mL protein kinase C isolated from rat brain, and stopping the reaction with 125 µL of 0.24 M phosphoric acid (+ 2 μg/mL internal standard). Preparation of reaction mixture and brain extract is described by Tammela et al. [29] , with the exception that [ 32 P] ATP was replaced with normal ATP. After 12 min enzymatic reaction, samples from the 96-well plates were collected into a 384-well filter plate and filtered with centrifugation at 2900 g for 10 min. The wells were covered with mineral oil to prevent evaporation before LC/MS quantitation of the product, phosphopeptide FKKS(p)FKL-NH 2 . To control electrospray ionization suppression/enhancement, FKKS(p)FKL peptide containing 13 C-15 N-labelled phenylalanine was used as internal standard. Relative PKC activity (%) was calculated by comparing the product phosphopeptide [M-H]signals from a well with the fraction with the signal from a well without extract, and then correcting all the relative activities with the signal intensities of the internal standard. The whole assay for 384 samples took about 1.5 h. One 384 well plate could be analyzed in 27.2 h. Fractionation: Fractionation was performed with an Agilent 1100 Series HPLC System with a Luna C8 (2) column (150 × 2 mm; 5 μm particle size, Phenomenex, USA), gradient elution with a flow rate of 0.15 mL min -1 and detection at 254 nm wavelength. The gradient profile is given in Figure 1 . The mobile phase consisted of 0.1% formic acid and 0.1% formic acid in isopropanol. Sample injection volume was 10 μL and fractions were collected at 30 second intervals onto 96-well plates containing 50 μL DMSO/well. Fractions on the plate were then concentrated with a vacuum centrifuge (speed vac) for 30 min and 3 μL of the remaining fraction from each well was used for PKC-assay.
